|Does Prolonged Combined Androgen Blockade Have Survival Benefits Over Short-Term Combined Androgen Blockade Therapy?|
|M. F. Sarosdy, P. F. Schellhammer, R. Johnson, et al.|
|Abramson Cancer Center of the University of Pennsylvania|
| Last Modified: November 1, 2001
Reviewers: Li Liu, MD
IntroductionThe therapeutic value of combined androgen blockade (CAB), the pairing of antiandrogen therapy with medical or surgical castration for the treatment of advanced prostate cancer, has been investigated over the last few decades. However, the optimal duration of CAB treatment remains an open question. In this study, the researchers assessed the survival difference between patients who had prolonged and short-term CAB treatment.
MethodA total of 813 patients with stage D2 prostate cancer received an antiandrogen, either 50 mg bicalutamide once daily or 250 mg flutamide t.i.d. The patients also received a monthly depot preparation of a luteinizing hormone-releasing hormone agonist, either 7.5 mg leuprolide or 3.6 mg goserelin.
DiscussionIn this study, patients with stage D2 prostate cancer who received combined androgen blockade therapy for 120 days tended to live longer than those who received shorter-term therapy. The immediate question would be how long is long enough. Since CAB treatment dose has long-term side effects, more studies are needed to evaluate the optimal duration of CAB treatment.